News

Adults using Kalydeco, Trikafta show lung function, nutrition gains

Adults using Kalydeco (ivacaftor) or Trikafta (ivacaftor/tezacaftor/elexacaftor) to treat their cystic fibrosis (CF) showed gains in lung function and nutritional status, according to a real-world, observational study in Australia. In contrast, no significant improvements in lung function were seen in adults or children with CF using Orkambi (ivacaftor/lumacaftor)…

Children as young as 2 now may use digestion aid Relizorb

The U.S. Food and Drug Administration (FDA) will allow children with cystic fibrosis (CF) as young as age 2 to use Relizorb, an enzyme cartridge that connects with an enteral feeding tube to provide easier digestion of fats. “This additional RELiZORB clearance represents access for approximately 25% of…

Support groups, clear advice needed by parents living with CF

As more adults with cystic fibrosis (CF) choose to become parents, they face unique challenges in balancing the responsibilities of caring for their children and managing their disease, a study highlights. Researchers outlined several areas where care teams could be of help, such as working with prospective parents to…

3D MRI of lungs seen to help measure Trikafta response in study

A three-dimensional MRI scan of the lungs can be used to monitor responses by cystic fibrosis (CF) patients to the approved CF medication Trikafta (elexacaftor/tezacaftor/ivacaftor), a new study reports. Indeed, the new 3D technology was found to work better than traditional two-dimensional MRI scans in assessing the effects of Trikafta…

Porosome now seeking US patent to cover new treatment for CF

Porosome Therapeutics is seeking a U.S. patent that would cover its “radically new and distinctive” technology platform for the treatment of cystic fibrosis (CF) and other health conditions, the company said in a press release. Its platform works by targeting a cellular structure called the porosome. The global…